Cellectar Biosciences (CLRB) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 72.1% versus a loss of 96.4%. Over five years, CLRB leads with a -99.6% price change compared with -99.7% for VTGN. Cellectar Biosciences is the larger company by market cap ($8.0 million vs $7.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | VTGN |
|---|---|---|
| Share price | $0.797 | $0.1636 |
| Market cap | $8.00M | $7.56M |
| 1-day change | -11.50% | -12.33% |
| YTD return | -72.98% | -75.21% |
| 1-year return | -72.13% | -96.44% |
| 5-year return | -99.63% | -99.72% |
| EPS (TTM) | $-2.34 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.27M |
| Revenue growth (YoY) | — | +161.11% |
| Net income (latest FY) | $-21.79M | $-69.69M |
| Operating margin | — | -5683.69% |
| Net margin | — | -5491.33% |
| 52-week high | $4.70 | $5.14 |
| 52-week low | $0.7596 | $0.16 |
| Distance from 52-week high | -83.04% | -96.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +1342.91% | +511.25% |
| Average volume | 97.96K | 10.30M |
| Shares outstanding | 10.04M | 46.19M |
| Employees | 11 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed VTGN by 24.3 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
CLRB vs VTGN FAQ
Which is bigger, Cellectar Biosciences or Vistagen Therapeutics?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $8.00M compared with $7.56M for Vistagen Therapeutics (VTGN).
Which stock has performed better over the past year, CLRB or VTGN?
CLRB returned -72.13% over the past 12 months, compared with -96.44% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.